These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 19720283)

  • 1. Reproducibility of the kinetic analysis of 3'-deoxy-3'-[(18)F]fluorothymidine positron emission tomography in mouse tumor models.
    Choi SJ; Kim SY; Kim SJ; Lee JS; Lee SJ; Park SA; Lee SJ; Yun SC; Im KC; Oh SJ; Kim SW; Kim JS; Ryu JS; Moon DH
    Nucl Med Biol; 2009 Oct; 36(7):711-9. PubMed ID: 19720283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic modeling of 3'-deoxy-3'-18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice.
    Kim SJ; Lee JS; Im KC; Kim SY; Park SA; Lee SJ; Oh SJ; Lee DS; Moon DH
    J Nucl Med; 2008 Dec; 49(12):2057-66. PubMed ID: 18997037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
    Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.
    Muzi M; Vesselle H; Grierson JR; Mankoff DA; Schmidt RA; Peterson L; Wells JM; Krohn KA
    J Nucl Med; 2005 Feb; 46(2):274-82. PubMed ID: 15695787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging of thymidine kinase 1 activity after 5-fluorouracil treatment in a mouse tumor model.
    Hong IK; Kim SY; Chung JH; Lee SJ; Oh SJ; Lee SJ; Oh J; Ryu JS; Kim TW; Kim DY; Moon DH
    Anticancer Res; 2014 Feb; 34(2):759-66. PubMed ID: 24511010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography.
    de Langen AJ; Klabbers B; Lubberink M; Boellaard R; Spreeuwenberg MD; Slotman BJ; de Bree R; Smit EF; Hoekstra OS; Lammertsma AA
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):389-95. PubMed ID: 18931838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.
    Bradbury MS; Hambardzumyan D; Zanzonico PB; Schwartz J; Cai S; Burnazi EM; Longo V; Larson SM; Holland EC
    J Nucl Med; 2008 Mar; 49(3):422-9. PubMed ID: 18287265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy.
    Menda Y; Boles Ponto LL; Dornfeld KJ; Tewson TJ; Watkins GL; Schultz MK; Sunderland JJ; Graham MM; Buatti JM
    J Nucl Med; 2009 Jul; 50(7):1028-35. PubMed ID: 19525472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproducibility of static and dynamic (18)F-FDG, (18)F-FLT, and (18)F-FMISO MicroPET studies in a murine model of HER2+ breast cancer.
    Whisenant JG; Peterson TE; Fluckiger JU; Tantawy MN; Ayers GD; Yankeelov TE
    Mol Imaging Biol; 2013 Feb; 15(1):87-96. PubMed ID: 22644988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
    J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproducibility of 3'-deoxy-3'-(18)F-fluorothymidine microPET studies in tumor xenografts in mice.
    Tseng JR; Dandekar M; Subbarayan M; Cheng Z; Park JM; Louie S; Gambhir SS
    J Nucl Med; 2005 Nov; 46(11):1851-7. PubMed ID: 16269599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of 3'-deoxy-3'-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors.
    Yang YJ; Ryu JS; Kim SY; Oh SJ; Im KC; Lee H; Lee SW; Cho KJ; Cheon GJ; Moon DH
    Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):412-9. PubMed ID: 16404598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus.
    Han D; Yu J; Yu Y; Zhang G; Zhong X; Lu J; Yin Y; Fu Z; Mu D; Zhang B; He W; Huo Z; Liu X; Kong L; Zhao S; Sun X
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1235-41. PubMed ID: 19910143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
    Waldherr C; Mellinghoff IK; Tran C; Halpern BS; Rozengurt N; Safaei A; Weber WA; Stout D; Satyamurthy N; Barrio J; Phelps ME; Silverman DH; Sawyers CL; Czernin J
    J Nucl Med; 2005 Jan; 46(1):114-20. PubMed ID: 15632041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
    Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
    J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
    Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
    Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors.
    Brockenbrough JS; Souquet T; Morihara JK; Stern JE; Hawes SE; Rasey JS; Leblond A; Wiens LW; Feng Q; Grierson J; Vesselle H
    J Nucl Med; 2011 Aug; 52(8):1181-8. PubMed ID: 21764789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET for detecting tumor repopulation during fractionated radiotherapy of human FaDu squamous cell carcinoma in nude mice.
    Yue JB; Yang J; Liu J; Lee J; Cabrera AR; Sun XD; Bai GH; Li YH; Yu JM
    Radiother Oncol; 2014 Jun; 111(3):475-81. PubMed ID: 24813091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.
    Vesselle H; Grierson J; Muzi M; Pugsley JM; Schmidt RA; Rabinowitz P; Peterson LM; Vallières E; Wood DE
    Clin Cancer Res; 2002 Nov; 8(11):3315-23. PubMed ID: 12429617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.